First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers

Commentary on Gowinet al. (2014): Brain is behavior-methamphetamine dependence and recovery

(2014) Steve Shoptaw   ADDICTION

Treatment of rats with an anti-(+)-methamphetamine monoclonal antibody shortens the duration of action of repeated (+)-methamphetamine challenges over a one month period

(2014) Michael D. Hambuchen et al.   VACCINE

Pharmacological effects of two anti-methamphetamine monoclonal antibodies

(2014) Elizabeth M Laurenzana et al.   Human Vaccines & Immunotherapeutics

Altered cingulate and insular cortex activation during risk-taking in methamphetamine dependence: losses lose impact

(2013) Joshua L. Gowin et al.   ADDICTION

Preclinical characterization of an anti-methamphetamine monoclonal antibody for human use

(2013) Misty W Stevens et al.   mAbs

Monoclonal Antibodies as Pharmacokinetic Antagonists for the Treatment of (+)-Methamphetamine Addiction

(2012) S. Michael Owens et al.   CNS & Neurological Disorders-Drug Targets

Anti-(+)-Methamphetamine Monoclonal Antibody Antagonists Designed to Prevent the Progression of Human Diseases of Addiction

(2010) W B Gentry et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A review of the clinical pharmacology of methamphetamine

(2009) Christopher C. Cruickshank et al.   ADDICTION

Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults

(2009) Leonard E. Weisman et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Raxibacumab for the Treatment of Inhalational Anthrax

(2009) Thi-Sau Migone et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Effect of a Chimeric Human/Murine Anti-Cocaine Monoclonal Antibody on Cocaine Self-Administration in Rats

(2008) A. B. Norman et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS